- Home
- TYL vs BIIB Comparison
TYL vs BIIB Comparison
Compare TYL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYL
- BIIB
- Stock Information
- Founded
- TYL 1966
- BIIB 1978
- Country
- TYL United States
- BIIB United States
- Employees
- TYL N/A
- BIIB N/A
- Industry
- TYL Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TYL Technology
- BIIB Health Care
- Exchange
- TYL Nasdaq
- BIIB Nasdaq
- Market Cap
- TYL 27.2B
- BIIB 25.1B
- IPO Year
- TYL N/A
- BIIB 1991
- Fundamental
- Price
- TYL $622.84
- BIIB $157.78
- Analyst Decision
- TYL Strong Buy
- BIIB Buy
- Analyst Count
- TYL 13
- BIIB 25
- Target Price
- TYL $642.62
- BIIB $258.57
- AVG Volume (30 Days)
- TYL 295.2K
- BIIB 1.6M
- Earning Date
- TYL 10-23-2024
- BIIB 10-30-2024
- Dividend Yield
- TYL N/A
- BIIB N/A
- EPS Growth
- TYL 47.95
- BIIB 10.05
- EPS
- TYL 5.48
- BIIB 11.06
- Revenue
- TYL $2,077,606,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- TYL $10.57
- BIIB N/A
- Revenue Next Year
- TYL $10.43
- BIIB N/A
- P/E Ratio
- TYL $113.80
- BIIB $14.26
- Revenue Growth
- TYL 8.04
- BIIB N/A
- 52 Week Low
- TYL $397.80
- BIIB $153.62
- 52 Week High
- TYL $638.56
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- TYL 54.53
- BIIB 33.43
- Support Level
- TYL $616.04
- BIIB $158.44
- Resistance Level
- TYL $638.56
- BIIB $162.62
- Average True Range (ATR)
- TYL 10.69
- BIIB 3.19
- MACD
- TYL 0.63
- BIIB 0.90
- Stochastic Oscillator
- TYL 63.03
- BIIB 35.65
About TYL Tyler Technologies Inc.
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.